Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Greg Rosenn

Neurology with Special Qualifications in Child Neurology Plainview, NY Medical Doctor

NPI 1598707697 CMS profile 162384

185 Express St Ste 400, Plainview, NY 11803

Open in the dashboard

General payments

$33,918

766 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Greg Rosenn of Plainview, NY is reported in the CMS Open Payments database as having received $33,918 across 766 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,679 79
2024 General $1,702 89
2023 General $2,981 82
2022 General $6,690 165
2021 General $12,254 178
2020 General $1,543 85
2019 General $7,070 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Greg Rosenn
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Greg Rosenn were reported at $1,679. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Greg Rosenn Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $7,070 $262 $68–$1,313 $163
2020 $1,543 $188 $46–$1,222 $114
2021 $12,254 $183 $45–$1,356 $132
2022 $6,690 $229 $72–$1,177 $149
2023 $2,981 $269 $93–$1,195 $160
2024 $1,702 $300 $98–$1,428 $164
2025 $1,679 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tris Pharma Inc $16,627 114 payments
  2. Supernus Pharmaceuticals, Inc. $9,018 256 payments
  3. Neurelis, Inc. $1,243 43 payments
  4. Ironshore Pharmaceuticals Inc. $1,189 55 payments
  5. Neos Therapeutics, LP $1,146 85 payments
  6. UCB, Inc. $917 37 payments
  7. Corium, Inc. $902 41 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $691 37 payments
  9. Vertical Pharmaceuticals, LLC $433 23 payments
  10. Collegium Pharmaceutical, Inc. $328 12 payments
  11. Other $1,426 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $13,950 13 payments
  2. Food and Beverage $12,409 737 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,500 5 payments
  4. Travel and Lodging $1,038 10 payments
  5. Gift $20 1 payment
Products named General payments · program years 2019–2025
  1. Dyanavel XR $15,911 68 payments
  2. Quillichew ER Adhd $9,576 22 payments
  3. Quillivant $9,558 19 payments
  4. QELBREE Psychology $5,844 172 payments
  5. VALTOCO $1,243 43 payments
  6. Quillichew ER Adhd $1,167 13 payments
  7. Quillivant XR $1,021 3 payments
  8. Azstarys $902 41 payments
  9. COTEMPLA XR-ODT $853 65 payments
  10. Qelbree Viloxazine Hydrochloride $849 64 payments
  11. Other $6,456 327 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

766 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record